Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

Inclusion Criteria: * Histologic diagnosis of gastric neuroendocrine tumor. * Clinical diagnosis of Type I gastric NET: neuroendocrine tumor arising from atrophic body gastritis (ABG diagnosis should be based on hypergastrinemia and histological confirmation of gastric body atrophy on multiple biopsies performed in gastric antrum and body). * Previous esophagogastroduodenoscopy: all visible NETs resected with R0 margin, confirmed no visible gastric NETs left, multiple biopsies taken to evaluate gastric atrophy and ECL status. * No tumor metastases confirmed by endoscopic ultrasonography, CT scan or somatostatin receptor scintigraphy. * SSA therapy is recommended by physician for disease management, and has not yet begun. * Written informed consent obtained prior to treatment to be consistent with local regulatory requirements. Exclusion Criteria: * Pathological grading as G3 NET (Ki-67\>20%). * Patients with a known hypersensitivity to somatostatin analogs. * Known gallbladder or bile duct disease, acute or chronic pancreatitis. * Known medical condition related with prolonged QT interval. * Pregnant or lactating women. * Patients with serious complicated infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy. * Patients with any concurrent active malignancy other than non-melanoma skin cancers or carcinoma-in-situ of the cervix. Patients with previous malignancies but without evidence of disease for \> 5 years will be allowed to enter the trial. * Patients with a history of non-compliance to medical regimens.